{"title":"Naproxen Induced Psoriasis: A Case Report","authors":"Vageeshwari Devuni","doi":"10.31142/IJTSRD24004","DOIUrl":null,"url":null,"abstract":"Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/ by/4.0) ABSTRACT Psoriasis is a chronic inflammatory skin disorder clinically characterized by erythematous, sharply demarcated papules and rounded plaques covered by silvery micaceous scale. There are several drugs that have been associated with the initiation, exacerbation, and aggravation of psoriasis. Understanding the pathophysiology can provide clues to treatment and management of druginduced and drug-aggravated psoriasis, which may be indistinguishable from idiopathic psoriasis. The clinical manifestations of drug-associated psoriasis can range from Plaque type psoriasis to severe Erythroderma, thus warranting astute and sustained clinical observation. Some factors known to trigger psoriasis include smoking, alcohol consumption, body mass index, trauma, infection, endocrine disorders, drugs. Drugs that appear to have a strong relationship to psoriasis are beta-blockers, lithium, synthetic antimalarials, NSAIDS and tetracyclines. Non steroidal anti inflammatory drugs(NSAIDS) are a class of medications used for treatment of pain and arthritides. It is important for clinicians to recognize NSAIDS as potential exacerbators of psoriasis. Exacerbation of psoriasis and arthritis may coincidently occur simultaneously with the use of NSAIDS.","PeriodicalId":14446,"journal":{"name":"International Journal of Trend in Scientific Research and Development","volume":"33 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Trend in Scientific Research and Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31142/IJTSRD24004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
萘普生诱发银屑病1例报告
版权所有©2019由作者和《国际科学研究与发展趋势杂志》所有。摘要牛皮癣是一种慢性炎症性皮肤病,临床特征为红斑、界限分明的丘疹和覆盖有银色云母鳞片的圆形斑块。有几种药物与牛皮癣的发病、恶化和加重有关。了解病理生理学可以为药物性和药物加重型银屑病的治疗和管理提供线索,这可能与特发性银屑病难以区分。药物相关性银屑病的临床表现可以从斑块型银屑病到严重的红皮病,因此需要敏锐和持续的临床观察。一些已知的触发牛皮癣的因素包括吸烟、饮酒、体重指数、创伤、感染、内分泌失调、药物。与牛皮癣有密切关系的药物有-受体阻滞剂、锂、合成抗疟药、非甾体抗炎药和四环素。非甾体抗炎药(NSAIDS)是一类用于治疗疼痛和关节炎的药物。对于临床医生来说,认识到非甾体抗炎药是牛皮癣的潜在加重因素是很重要的。银屑病和关节炎的恶化可能与使用非甾体抗炎药同时发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。